The stem cell therapy market is on an exponential rise, projected to grow from $0.48 billion in 2026 to $3.65 billion by 2035, driven by innovation and demand.

Trailhead Biosystems announced an additional $20 million in funding, bringing total financing to $40 million for expanding its iPSC-derived human cell products for biomedical research.

Celaid Therapeutics and AGC have partnered to enhance iPSC-derived hematopoietic stem and progenitor cell technologies, tackling major challenges in cell therapy production.

Shineco Inc. establishes a new division focused on integrating biological cell assets with blockchain technology, enhancing accessibility and efficiency in stem cell utilization.

Trailhead Biosystems has launched TrailBio® hematopoietic progenitor cells derived from iPSCs, improving research in hematopoietic diseases and drug screening.

Trailhead Biosystems has launched hematopoietic progenitor cells derived from iPSCs, offering researchers a reliable tool for hematopoietic research and drug development.

Discover how I Peace, Inc. is transforming personalized medicine with groundbreaking iPSC technology, offering new hope for regenerative treatments and therapies.